TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02013492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease.
Study: NCT04069130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg of BIA 5-1058
Description: 1 x 400 mg capsule Oral, Fasted
Study: NCT03278535

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed

Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed
Study: NCT03907163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Capsules containing 5 mg Dronabinol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules identical in appearance to dronabinol
Study: NCT03547401

Intervention type: DEVICE
Intervention: Ankle Non-invasive Blood pressure measurement
Description: Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).

Intervention type: DEVICE
Intervention: Arm Non-invasive Blood pressure measurement
Description: Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
Study: NCT02565563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitisation Reprocessing
Description: The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitisation Reprocessing
Description: The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath measuring Heart Rate Variability (HRV)
Description: This small device will be attached to the patients finger to allow their heart rate variability to be measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath measuring Heart Rate Variability (HRV)
Description: This small device will be attached to the patients finger to allow their heart rate variability to be measured.
Study: NCT02393872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Description: Community-based intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Description: Community-based intervention.
Study: NCT02623010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imbruvica
Description: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
Study: NCT04107922

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glicoset
Description: Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo
Study: NCT01654601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWCZP
Description: Multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWCZP
Description: Multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril
Description: multiple-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril
Description: multiple-dose
Study: NCT01119898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNSAID Gel
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Study: NCT01834508

Intervention type: DRUG
Group type: OTHER
Intervention: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
Study: NCT01122381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethosuximide
Description: ethosuximide (ESX)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo
Study: NCT00116844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valtrex 1g once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valtrex 1g once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT02640248

Intervention type: DEVICE
Intervention: Cuff ETT
Study: NCT04418635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo
Description: the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo
Description: the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
Study: NCT02977559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction Disposable
Description: Device for ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway AuraGain
Description: Ventilation device
Study: NCT03907527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3005 UltraCAR-T cells
Description: Given IP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3005 UltraCAR-T cells
Description: Given IV
Study: NCT02294396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast
Study: NCT01873430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Study: NCT04472442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham hypoxia
Description: Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr).
Study: NCT01963858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional relaxation
Description: Functional relaxation during colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No relaxation
Description: No relaxation during colonoscopy
Study: NCT00660764

Intervention type: DRUG
Intervention: Rosuvastatin
Description: Oral
Study: NCT02294396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidafenacin tablet
Description: orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
Study: NCT01437163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TopHat 655 rejuvenation system
Description: TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser and/or Light Hair Rejuvenation System
Description: A red incandescent light source replaces all lasers and light emitting diodes.
Study: NCT01356680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 30Gy IF-RT (Involved-Field Radiotherapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30Gy IN-RT (Involved-Node Radiotherapy)
Study: NCT00265135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
Study: NCT05660590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complex decongestive physiotherapy with low pressure compression bandage
Description: both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complex decongestive physiotherapy with high pressure compression bandage
Description: complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
Study: NCT04023071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning agent
Study: NCT02294396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine capsule
Description: orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
Study: NCT04023071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study: NCT02765919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy of 9 Gy in 2 fractions
Description: Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR Brachytherapy of 7 Gy in 3 fractions
Description: Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
Study: NCT03680625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive Distraction
Description: Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
Study: NCT02964676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ab interno trabeculectomy with Trabectome
Description: 123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: 123 PACG will be recruited to receive trabeculectomy to reduce IOP
Study: NCT05840861

Intervention type: DRUG
Intervention: Vortioxetine
Description: All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.

Intervention type: DRUG
Intervention: Quetiapine
Description: All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
Study: NCT00811382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)
Description: Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)
Description: Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
Study: NCT01135433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study: NCT00766675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Study: NCT01746095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin hydrochloride inhalation powder
Description: There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder
Study: NCT01575353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high-flow
Description: The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
Study: NCT00883506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 40 mg Tablet (Zestril) under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet under fed conditions.
Study: NCT03099330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: TQ-B3139 p.o. qd